Home › Aortic Valve Stenosis › NCT06777368
REdo tranScatheter Aortic Valve Replacement for Transcatheter aOrtic Valve failuRE
RecruitingObservational study
Who can join
Ages 18 to 105 · All sexes
Full eligibility criteria
Inclusion Criteria: * BVF of a TAV (either Medtronic or Edwards) requiring redo TAVR Exclusion Criteria: * BVF due solely to paravalvular regurgitation * Active endocarditis * Untreated acute valve thrombosis * Life-expectancy less than 1-year * Subject is less than legal age of consent, legally incompetent, or otherwise vulnerable * Participating in another study that may influence the outcome of this study
About the study
The purpose of this study is to generate clinical evidence on valve safety and performance in subjects treated by redo Transcatheter Aortic Valve Replacement (TAVR).
What is being tested
- Medtronic TAV (device)
- Edwards TAV (device)
Sponsor: Medtronic Cardiovascular · Participants: 225 · Started: Feb 6, 2025
Contact the study team
- RESTORE Study Clinical Team · Phone: 763 514 4000
Official record on ClinicalTrials.gov — NCT06777368
Locations in the U.S.
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.